查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1544663

自體免疫性溶血性貧血治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Autoimmune Hemolytic Anemia Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 250 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球自體免疫溶血性貧血 (AIHA) 治療市場預計 2024 年至 2032 年複合年成長率為 6%。自體免疫性溶血性貧血是一種免疫系統錯誤地攻擊紅血球的疾病，由於人們所認知的提高和診斷能力的提高，它越來越受到人們的認知。該領域研究數量的激增將為市場提供支持。

2024年5月，法國的一項回顧性研究顯示，三分之一患有嚴重自體免疫性溶血性貧血（AIHA）（包括冷凝集素病）的成年人在一週後對靜脈注射免疫球蛋白（ IVIG）作為輔助治療產生正面反應。值得注意的是，超過一半 (57%) 的可取得血液資料的患者在 IVIG 給藥兩週後表現出治療反應。

此外，該領域正在進行的研究和開發正在推出新的治療方法，這些治療方法具有增強的功效和最小化的副作用，從而推動了市場的成長。先進治療方法的激增，加上自體免疫疾病發生率的上升，極大地促進了 AIHA 治療市場的擴張。

AIHA 治療市場根據疾病類型、治療類型、給藥途徑、配銷通路和地區進行分類。

按疾病類型、治療類型和地區細分，AIHA 治療市場預計寒冷性自體免疫溶血性貧血細分市場將顯著成長。冷 AIHA 是由於低溫誘導產生針對紅血球的冷凝集素而引起的，它帶來了獨特的治療挑戰。然而，針對感冒 AIHA 的標靶治療和創新方法的進步有望推動這一領域的成長。改進的診斷工具和客製化的治療計劃正在擴大這些療法的採用，促進市場的整體擴張。

免疫抑制劑領域有望佔據 AIHA 治療市場的很大一部分。這些藥物包括皮質類固醇和尖端生物療法，透過抑制免疫系統對紅血球的誤導性攻擊，在治療自體免疫疾病方面發揮關鍵作用。它們不僅可以緩解 AIHA 患者的症狀，還可以防止病情復發。隨著先進免疫抑制藥物供應的激增以及對更有效治療方法的不斷研究，對這些療法的需求正在上升。此外，免疫抑制方案的創新有望提高患者的治療效果並刺激市場成長。

2024 年至 2032 年間，歐洲將在 AIHA 治療市場擴張中發揮關鍵作用。該地區強大的醫療基礎設施在大量醫學研究投資的支持下，為先進 AIHA 療法的開發和採用鋪平了道路。歐洲國家以其嚴格的監管框架確保新興療法的安全性和有效性，為市場成長創造了有利的環境。再加上歐洲自體免疫疾病的高盛行率以及領先製藥公司倡導創新研究的存在，這些因素共同推動了該地區 AIHA 治療市場的發展。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 全球自體免疫疾病及相關疾病的盛行率不斷上升
      • 生物技術和免疫學的進展
      • 醫療保健專業人員和患者的意識不斷提高
    • 產業陷阱與挑戰
      • 與新療法和持續治療方案相關的高成本
      • 新治療方式的監管挑戰和嚴格的核准流程
  • 成長潛力分析
  • 管道分析
  • 未來市場趨勢
  • 監管環境
  • 專利分析
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按疾病類型，2021 - 2032

  • 主要趨勢
  • 溫性自體免疫溶血性貧血
  • 寒冷性自體免疫溶血性貧血

第 6 章：市場估計與預測：按治療類型，2021 - 2032 年

  • 主要趨勢
  • 皮質類固醇
  • 免疫抑制劑
  • 其他治療類型

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

  • 主要趨勢
  • 可注射
  • 口服
  • 其他給藥途徑

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥房
  • 電子商務
  • 其他分銷管道

第 9 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Baxter International Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Johnson and Johnson Services, Inc.
  • Merck and Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Takeda Pharmaceutical Company Limited
簡介目錄
Product Code: 10198

Global Autoimmune Hemolytic Anemia (AIHA) Treatment Market is expected to register a 6% CAGR from 2024 to 2032. This expansion is largely attributed to advancements in treatment options and a growing prevalence of the disease. Autoimmune hemolytic anemia, a condition where the immune system mistakenly attacks red blood cells, is becoming increasingly recognized due to heightened awareness and improved diagnostic capabilities. The boom in number of studies across the field will support the market.

In May 2024, a retrospective study from France revealed that one-third of adults with severe autoimmune hemolytic anemia (AIHA), including cold agglutinin disease, responded positively to intravenous immunoglobulins (IVIG) as an adjunct therapy after a week. Notably, over half (57%) of the patients with accessible blood data exhibited a treatment response two weeks post-IVIG administration.

Moreover, ongoing research and development in the field are introducing new treatments that boast enhanced efficacy and minimized side effects, fueling the market's growth. The surge in advanced therapy availability, coupled with the rising incidence of autoimmune disorders, significantly bolsters the AIHA treatment market's expansion.

The AIHA treatment market is categorized based on disease type, treatment type, route of administration, distribution channel, and region.

Segmented by disease type, treatment type, and region, the AIHA treatment market anticipates notable growth in the cold autoimmune hemolytic anemia segment. Cold AIHA, which arises from cold temperatures inducing the production of cold agglutinins that target red blood cells, poses distinct treatment challenges. However, advancements in targeted therapies and innovative approaches specifically for cold AIHA are poised to propel growth in this segment. Improved diagnostic tools and customized treatment plans are amplifying the adoption of these therapies, bolstering the market's overall expansion.

The immunosuppressive agents segment is on track to secure a substantial portion of the AIHA treatment market. These agents, encompassing corticosteroids and cutting-edge biological therapies, are pivotal in managing autoimmune disorders by curbing the immune system's misguided attacks on red blood cells. They not only alleviate symptoms but also stave off relapses in AIHA patients. With a surge in advanced immunosuppressive drug availability and continuous research into more potent treatments, the demand for these therapies is on the rise. Furthermore, innovations in immunosuppressive options promise to elevate patient outcomes and stimulate market growth.

Between 2024 and 2032, Europe is set to play a pivotal role in the AIHA treatment market expansion. The region's robust healthcare infrastructure, bolstered by substantial medical research investments, paves the way for the development and uptake of advanced AIHA treatments. European nations, with their stringent regulatory frameworks, ensure the safety and efficacy of emerging therapies, creating a favorable landscape for market growth. Coupled with Europe's high autoimmune disorder prevalence and the presence of leading pharmaceutical firms championing innovative research, these factors collectively propel the AIHA treatment market in the region.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of autoimmune disorders and associated conditions, globally
      • 3.2.1.2 Advances in biotechnology and immunology
      • 3.2.1.3 Rising awareness among healthcare professionals and patients
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High costs associated with novel therapies and ongoing treatment regimens
      • 3.2.2.2 Regulatory challenges and stringent approval processes for new treatment modalities
  • 3.3 Growth potential analysis
  • 3.4 Pipeline analysis
  • 3.5 Future market trends
  • 3.6 Regulatory landscape
  • 3.7 Patent analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Warm autoimmune hemolytic anemia
  • 5.3 Cold autoimmune hemolytic anemia

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Corticosteroids
  • 6.3 Immunosuppressive agents
  • 6.4 Other treatment types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Injectable
  • 7.3 Oral
  • 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacy
  • 8.3 Retail pharmacy
  • 8.4 E-commerce
  • 8.5 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 AbbVie Inc.
  • 10.2 Amgen Inc.
  • 10.3 AstraZeneca
  • 10.4 Biogen Inc.
  • 10.5 Bristol-Myers Squibb Company
  • 10.6 Baxter International Inc.
  • 10.7 Eli Lilly and Company
  • 10.8 Gilead Sciences, Inc.
  • 10.9 Johnson and Johnson Services, Inc.
  • 10.10 Merck and Co., Inc.
  • 10.11 Novartis AG
  • 10.12 Pfizer Inc.
  • 10.13 F. Hoffmann-La Roche Ltd
  • 10.14 Sanofi
  • 10.15 Takeda Pharmaceutical Company Limited